Activated protein C for the treatment of severe sepsis

Clinical Microbiology and Infection

Volumn 15, Issue 4, 2009, Pages 319-324

  Houston, Gordon ^a   Cuthbertson, B H ^a,b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Drotrecogin alfa (activated); Recombinant activated protein C; Review; Sepsis; Sepsis treatment; Severe sepsis; Xigris

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; PLACEBO;

ADAPTIVE IMMUNITY; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; LYMPHOCYTE COUNT; MORTALITY; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPSIS; SURVIVAL RATE;

EID: 65449160155     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02751.x     Document Type: Review

References (32)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States. Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 16: 1546-1554.
3. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of life in survivors of sepsis. Short Form 36: A valid and reliable measure of health-related quality of life. Crit Care Med 2000; 28: 3599-3605.
4. Bernard GR, Vincent JL, Laterre PF et al. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 10: 699-709.
5. Cinel I, Dellinger RP. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007; 20: 345-352.
6. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock 2001; 16: 83-96.
7. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005; 8: 5110-5118.
8. Le Tulzo Y, Pangault C, Gacouin A et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 18: 487-494.
9. Guisset O, Dilhuydy MS, Thiebaut R et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007; 33: 148-152.
10. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 13: 1027-1030.
11. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
12. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001; 120: 915-922.
13. Fijnvandraat K, Derkx B, Peters M et al. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73: 15-20.
14. Shorr AF, Bernard GR, Dhainaut JF et al. Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. Crit Care 2006; 10: R92.
15. Guo H, Liu D, Gelbard H et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 4: 563-572.
16. Cheng T, Liu D, Griffin JH et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342.
17. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 2: 238-247.
18. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 15: 1869-1878.
19. FDA clinical review drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] xigris. 2001. Approved: 21 November 2001. Available at: http://www.fda.gov/cder/biologics/review/ droteli112101r1.pdf
20. Abraham E, Laterre PF, Garg R et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 13: 1332-1341.
21. Nadel S, Goldstein B, Williams MD et al. REsearching severe Sepsis and Organ dysfunction in children: A gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 9564: 836-843.
22. Angus DC, Laterre PF, Helterbrand J et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32: 2199-2206.
23. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials [see comment]. Crit Care Med 2003; 1 (suppl): S94-S96.
24. Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C. Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial. Crit Care Med 2005; 33: 2426-2428.
25. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007; 33: 396-399.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829.
27. Vincent JL, Bernard GR, Beale R et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266-2277.
28. Dellinger RP. Recombinant activated protein C: The key is clinical assessment of risk of death, not subset analysis. Crit Care 2006; 10: 114.
29. Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis [see comment]. Crit Care Med 2003; 1 (suppl): S85-S93.
30. Rocker G, Cook D, Sjokvist P et al. Clinician predictions of intensive care unit mortality. Crit Care Med 2004; 32: 1149-1154.
31. Marti-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis [update of Cochrane Database Syst Rev 2007;(3):CD004388; PMID: 17636755]. Cochrane Database Syst Rev 2008; 1: 004388.
32. Bae JS, Yang L, Manithody C, Rezaie AR. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem 2007; 12: 9251-9259.